vimarsana.com

Latest Breaking News On - Adverse events - Page 12 : vimarsana.com

AACR 2024: PDC*line Pharma presents interim clinical results from last cohort of patients in phase I

Intermediary results of high dose PDC lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and.

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.